Biotechnology Hutchison China MediTech Limited, a biopharma which is majority owned by the conglomerate CK Hutchison Holdings and which goes by the name Chi-Med, has presented further data from the FRESCO Phase III study in 416 patients with locally advanced or metastatic colorectal cancer (CRC) at the ongoing 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. 5 June 2018